Lexicon stock: buy or sell?
February 26th, 2020
Lexicon Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of pharmaceutical products for the treatment of human diseases.
Should I buy Lexicon stock?You can't be a successful trader if you don't follow a methodolgy or system that assist you in choosing companies and the correct market timing. That's why is so important to choose your own trading strategy that matches with your character as inversor. At Stocks2.com, we like to use very simple but trusted and powerful trend following trading strategies. Simple things usually work the best.
Currently, Lexicon stock doesn't match any of these trading strategies, so our recommendation is not to buy.
|New all-time high||No|
|New 52 week high||No|
|Price crossing up 200d MA||No|
|100d MA crossing up 200d MA||No|
Is Lexicon stock a buy?
Everyday, hundreds of stock ratings are published by financial analysts to indicate a particular stock's attractiveness.Unfortunately, we couldn't detect any rating for LXRX stock for the last 30 days.
Lexicon stock analysis
Lexicon Pharmaceuticals shares gained 0.35% to $2.86 today.
Shares of Lexicon gained a slightly good 0.35% and closed at $2.86. Since last December when LXRX stock price broke down the SMA200d line, it slid $-1.66 per share (-36.73%). LXRX marked a lower low and a lower high in the short term, defining a downward trend. Climbing above $3.28 would break this short term down trend and open possibilities for reversing this situation.
After sliding a scary -7.81% in a week last week, Lexicon Pharmaceuticals closed this week at $2.86 and boosted an astounding 6.32%. This week broke a red streak of 4 weeks.
Lexicon finally declined under the support line and now is sliding further looking for new supports. Since price and 40-weeks moving average lines crossed down late December 2019, LXRX fell $-1.55 per share (-35.15%). Stocks under the 40w moving average line are usually not recommended for average traders.
Lexicon stock price history
Lexicon stock went public on April 7th, 2000 with a price of $154.001. Since then, LXRX stock lost a -98.10%, with a yearly average of -5.20%.
1: Adjusted price after possible price splits or reverse-splits.
Lexicon stock historical price chart
LXRX stock reached 52-week highs on March at $8.39, and all-time highs 2000-07-21 with a price of 344.75.
Lexicon stock price targetHow much a stock will be priced tomorrow or next week is quite unpredictable However, many stock price predictions are published every day by banks, financial institutions and independent analysts. You should not follow the analysts' LXRX stock price predictions in the hope that they will be met as they may be wrong and not met. For the last 30 days we have not detected any price forecast for Lexicon Pharmaceuticals stock by any trusted analyst.
Financials and fundamental analysis
Earnings date and Earnings per ShareOn March, Lexicon didn't meet the expectations of the analysts and reported a scary EPS of $-0.16 per share when experts were expecting $-0.28.
|Quarter||Reporting date||Estimated EPS||Actual EPS||Surprise|
Annual financial resultsCompared to 2017, last anual revenues report draw a bloodcurdling decrease of -31.06% to $63.21 M dollars. In the same way, its earnings margin (compared to revenues) plummed to -190.71%, that is $-120.55 million.
|2013||$2.22 M||-||$-104.13 M-4690.5%||-|
|2014||$23 M||929.46%||$-100.29 M-438.8%||-3.68%|
|2015||$130 M||468.89%||$-4.68 M-3.6%||-95.33%|
|2016||$83 M||-35.90%||$-141.43 M-169.7%||2,920.70%|
|2017||$92 M||10.02%||$-122.99 M-134.1%||-13.04%|
|2018||$63 M||-31.06%||$-120.55 M-190.7%||-1.99%|
Quarterly financial resultsLexicon posted $17.39 million in revenues for 2018-Q4, a 153.69% up compared to previous quarter. Reported quarter income marked $-16.26 million with a profit margin of -93.46%. Profit margin rocketed a 307.83% compared to previous quarter when profit margin was -401.28%. When comparing sales to same quarter last year, Lexicon Pharmaceuticals sales marked a hair-raising slide and collapsed a -47.37%.
|2017-Q1||$18 M||-||$-34.89 M-190.8%||-|
|2017-Q2||$12 M||-34.12%||$-35.06 M-291.0%||0.49%|
|2017-Q3||$27 M||123.59%||$-30.72 M-114.0%||-12.37%|
|2017-Q4||$33 M||22.66%||$-28.38 M-85.9%||-7.63%|
|2018-Q1||$25 M||-23.72%||$-42.08 M-166.9%||48.27%|
|2018-Q2||$14 M||-45.44%||$-34.71 M-252.4%||-17.51%|
|2018-Q3||$7 M||-50.15%||$-27.51 M-401.3%||-20.73%|
|2018-Q4||$17 M||153.69%||$-16.26 M-93.5%||-40.92%|
Lexicon ownershipWhen you are planning to buy shares of a company, it's always worth to check its ownership structure.
Lexicon Pharmaceuticals shares owned by insiders (that is, founders, CEO, CTO, main executives or other management staff) currently counts a 0.98% of all shares.
Bearish positions for LXRX stock account 0.00%, no big difference from last month.
The following table compares ownership indicators for other stocks related to Lexicon Pharmaceuticals:
|Market cap||$303.9 M|
|Total shares||106.3 M|
|Float shares||40.6 M|
|- Institutional holdings (%)||102.1%|
|- Insider holdings (%)||1.0%|
|Shares in short selling||0.0%|
|Wednesday, February 26th, 2020|
|Day range||$2.79 - $3.00|
|Average true range||$0.18|
|50d mov avg||$3.67|
|100d mov avg||$3.71|
|200d mov avg||$3.88|
Lexicon performanceTo measure stock performance is always good to compare with competitors or related stocks. We compared Lexicon against in the following table: